STEMTECH CORPORATION ANNOUNCES LETTER OF INTENT TO ACQUIRE LIFE FACTOR RESEARCH
Stemtech Corporation (OTCQB: STEK) has issued a Letter of Intent to acquire Life Factor Research, enhancing its R&D capabilities in stem cell nutrition and related products. This acquisition is expected to position Stemtech at the forefront of advanced stem cell technology, allowing quicker market penetration of innovative health products. The collaboration aims to cater to an expanding market with a focus on anti-aging and longevity. The CEO of Life Factor Research highlights the potential for redefining market standards through this partnership.
- Acquisition of Life Factor Research enhances Stemtech's in-house R&D capabilities.
- Expected acceleration in market introduction of innovative health-benefit products.
- Potential to expand Independent Business Partner base, improving income opportunities.
- None.
MIRAMAR, FL, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Stemtech Corporation (“Stemtech”) (OTCQB: STEK), an innovative nutraceutical company and a pioneer in the field of stem cell nutrition, today announced that it has issued a Letter of Intent to acquire Life Factor Research, a scientific research and development company.
Stemtech Corporation President and Chief Operating Officer, John W. Meyer, said “the acquisition of Life Factor Research (LFR) provides Stemtech with an important in-house Research and Development Division which will provide all stem cell nutrition, other stem-ceuticals™, skin care and more cutting-edge ‘revolutionary’ stem cell products. This acquisition is made to position Stemtech at the very scientific forefront of advanced stem cell technology, developing more health-benefit products as well as expanding our Independent Business Partner base, enabling them to have a higher income earning opportunity.”
Charles S. Arnold, Stemtech Corporation Chairman and CEO stated that “with the addition of LFR to the Stemtech family of global companies, we will be able to develop more new health benefit products to provide improved quality of life, anti-aging and longevity products for our Independent Business Partners and numerous international customers.” In addition, “having LFR with their extensive expertise in new technologies enables Stemtech to bring more sophisticated products to market at a faster pace, which will spur the expansion we project. The stem cell industry on the whole is reporting tremendous growth prospects with substantial investments in stem pharma, stem cell therapy and stem cell nutrition. As Stemtech pioneered stem cell nutrition, so now is our time to accelerate further into the future, and this acquisition gives us the best research team to do so”.
Life Factor Research CEO, Charles “Cliff” Layton says “having spent the last 35-plus years building the relationships which have enabled LFR to participate in creating the proprietary formulas, using compounds and proven technologies, we are extremely optimistic as to what an alliance with Stemtech will afford us. Our desire to create and control category leading nutraceuticals has been and will continue to be our focus. When combined with the technologies and distribution present in the current Stemtech model, we see levels of success obtainable by working together that could very well redefine much of what the market holds as standards and platitudes today.”
About Life Factor Research
Life Factor Research (LFR) is a multifaceted technology company serving the nutraceutical space, established in March 2020. LFR bases its rapid amassing of assets to the decades of industry relationships formed prior to launching. LFR specializes in identifying market needs and trends, locating and aggregating innovative technologies, intellectual property, and proprietary ingredients to formulate, validate and produce products that are by design disruptive to the market and proprietary in nature. LFR is a relationship centric company that has unique strategic relationships in formulation and manufacturing. The Company’s focus is set on product concepts, formulas, patents, and scientific studies that support a uniqueness that is currently not being met in the industry. LFR's market separation is based on the most meaningful metric in play – scientifically validated performance. Innovative product development expands into therapeutic skincare, sleep, pain, systemic inflammation, and more.
LFR enjoys distribution partner relationships that reach into the Direct Sales space, Independent Representative world and has created and managed several online marketing campaigns, all of which are overseen from within the LFR ranks.
About Stemtech Corporation
Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc. which was founded in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, the Company underwent an extensive executive reorganization, and continued operations under new leadership. Stemtech specializes in creating products and formulas that are patent protected in the U.S. and in select international markets. The Company’s patented formulas help the release, circulation and migration of the body’s adult stem cells from its bone marrow. The Company markets its products under the following brands: RCM System, stemrelease3™, Stemflo® MigraStem, OraStem® (Oral Health Care), and D-Fuze™ (EMF blocker). Its nutraceutical products are all-natural, plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplement Health and Education Act (DSHEA). For more information, please visit www.stemtech.com.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on August 23, 2022. We undertake no duty to update any forward-looking statement, or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
Investor Relations:
Frank J. Pena, 908 675-0581
FAQ
What is the purpose of Stemtech's acquisition of Life Factor Research?
How will the acquisition impact Stemtech's business operations?
What advantages does Life Factor Research bring to Stemtech?
What is the stock symbol for Stemtech Corporation?
When was the Letter of Intent for the acquisition issued?
